Data on Cantargia’s antibodies in leukemia models published in international scientific journal

Lund, Sweden 11 August 2015 – Cantargia AB (CANTA:SS) today announces that a
scientific article on the use of Cantargia’s antibodies in preclinical models of
acute myeloid leukemia (AML) have been published in the respected international
journal Proceedings of the National Academy of Sciences of the United States of
America (PNAS).
The article, entitled “Antibodies targeting human IL1RAP (IL1R3) show
therapeutic effects in xenograft models of acute myeloid leukemia”, was written
by the research teams behind Cantargia. The article documents that Cantargia’s
antibodies targeting IL1RAP have been shown to have a potent anti-tumour effect
in preclinical models of AML.

The results show clearly that an antibody targeting IL1RAP functions in two
independent ways, partly by stimulating the immune system’s “NK cells” to kill
cancer cells and partly by blocking the signalling via IL1RAP.

“This article confirms our view that IL1RAP is an attractive target molecule for
the treatment of various forms of cancer. Our unique product candidate, CAN04,
uses two independent mechanisms to limit the growth of the cancer cells, which
is a very important and valuable property,” Göran Forsberg, CEO of Cantargia,
says.

The article is available at www.pnas.org

For further information, please contact:

Cantargia AB

Göran Forsberg, Ph.D.
CEO
Telephone: +46 46 275 62 60
E-mail: goran.forsberg@cantargia.com (goran.forsberg@cantargia.com)
Website (goran.forsberg@cantargia.com): www.cantargia.com